CLIA Kit for Tumor Necrosis Factor Related Apoptosis Inducing Ligand (TRAIL) Homo sapiens (Human) Sandwich CLIA

CD253; TNFSF10; APO2L; Apo2-L; TL2; TRAIL; Tumor Necrosis Factor Ligand Superfamily Member 10; Apo-2 Ligand

Add to Cart Distributors
Overview
Properties
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • CLIA Kit for Tumor Necrosis Factor Related Apoptosis Inducing Ligand (TRAIL) Packages (Simulation)
  • CLIA Kit for Tumor Necrosis Factor Related Apoptosis Inducing Ligand (TRAIL) Packages (Simulation)
  • CLIA Kit for Tumor Necrosis Factor Related Apoptosis Inducing Ligand (TRAIL) Results demonstration
  • SCA139Hu.jpg Typical Standard Curve
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Recovery

Matrices listed below were spiked with certain level of recombinant Tumor Necrosis Factor Related Apoptosis Inducing Ligand (TRAIL) and the recovery rates were calculated by comparing the measured value to the expected amount of Tumor Necrosis Factor Related Apoptosis Inducing Ligand (TRAIL) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 93-101 96
EDTA plasma(n=5) 98-105 101
heparin plasma(n=5) 93-101 96

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Tumor Necrosis Factor Related Apoptosis Inducing Ligand (TRAIL) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Tumor Necrosis Factor Related Apoptosis Inducing Ligand (TRAIL) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Tumor Necrosis Factor Related Apoptosis Inducing Ligand (TRAIL) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 99-105% 78-104% 84-94% 90-101%
EDTA plasma(n=5) 91-105% 96-104% 98-105% 93-103%
heparin plasma(n=5) 97-105% 96-103% 89-103% 86-103%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
Pre-coated, ready to use 96-well strip plate 1 Plate sealer for 96 wells 4
Standard 2 Standard Diluent 1×20mL
Detection Reagent A 1×120µL Assay Diluent A 1×12mL
Detection Reagent B 1×120µL Assay Diluent B 1×12mL
Substrate A 1×10mL Substrate B 1×2mL
Wash Buffer (30 × concentrate) 1×20mL Instruction manual 1

Assay procedure summary

1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 3 times;
5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
6. Aspirate and wash 5 times;
7. Add 100µL Substrate Solution. Incubate 10 minutes at 37°C;
8. Read RLU value immediately.

CLIA Kit for Tumor Necrosis Factor Related Apoptosis Inducing Ligand (TRAIL)

Test principle

The microplate provided in this kit has been pre-coated with an antibody specific to Tumor Necrosis Factor Related Apoptosis Inducing Ligand (TRAIL). Standards or samples are then added to the appropriate microplate wells with a biotin-conjugated antibody specific to Tumor Necrosis Factor Related Apoptosis Inducing Ligand (TRAIL). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. Then the mixture of substrate A and B is added to generate glow light emission kinetics. Upon plate development, the intensity of the emitted light is proportional to the Tumor Necrosis Factor Related Apoptosis Inducing Ligand (TRAIL) level in the sample or standard.;

Citations

  • Intranasal Administration of Recombinant TRAIL Down-Regulates CXCL-1/KC in an Ovalbumin-Induced Airway Inflammation Murine ModelPubmed:25506835
  • Soluble TRAIL Concentration in Serum Is Elevated in People with HypercholesterolemiaPubMed: 26633016
  • Non-alcoholic fatty liver disease, vascular inflammation and insulin resistance are exacerbated by TRAIL deletion in micepubmed:28507343
  • TRAIL and TRAIL Receptors as Prognostic Markers in Breast Cancer PatientsPubmed: 31183506
  • Nifuroxazide attenuates experimentally-induced hepatic encephalopathy and the associated hyperammonemia and cJNk/caspase-8/TRAIL activation in ratsPubmed: 32259601
  • Cardio-protective impact of gabapentin against doxorubicin-induced myocardial toxicity in rats; emphasis on modulation of inflammatory-apoptotic signalingPubmed: 33199237
  • Chemo-preventive effect of crocin against experimentally-induced hepatocarcinogenesis via regulation of apoptotic and Nrf2 signaling pathwaysPubmed: 32942000
  • Tranilast abrogates cisplatin©\induced testicular and epididymal injuries: An insight into its modulatory impact on apoptosis/proliferation34047436

Recommend products